We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
+$318M
Cap. Flow %
8.9%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 61.98%
2 Consumer Discretionary 13.38%
3 Technology 3.16%
4 Financials 1.15%
5 Communication Services 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
51
CALL
DELISTED
Epizyme, Inc
EPZM
$16.1M 0.45%
1,000,000
+750,000
+300% +$13.1M
TCOM icon
52
Trip.com Group
TCOM
$29.2B
$15.6M 0.44%
600,000
+135,000
+29% +$3.4M
FOLD
53
CALL
DELISTED
Amicus Therapeutics
FOLD
$15.1M 0.42%
1,000,000
– –
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$14.9M 0.42%
90,000
-30,000
-25% -$4.68M
ALNY icon
55
CALL
Alnylam Pharmaceuticals
ALNY
$38.6B
$14.8M 0.41%
+100,000
New +$13.5M
AUPH icon
56
Aurinia Pharmaceuticals
AUPH
$1.92B
$14.6M 0.41%
900,000
+150,000
+20% +$2.4M
VNET
57
VNET Group
VNET
$1.79B
$13.9M 0.39%
583,000
-417,000
-42% -$6.72M
IOVA icon
58
Iovance Biotherapeutics
IOVA
$2.04B
$13.7M 0.38%
500,000
-250,000
-33% -$8.22M
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$13.3M 0.37%
500,360
-87,765
-15% -$2.07M
YMAB
60
DELISTED
Y-mAbs Therapeutics
YMAB
$13M 0.36%
300,030
-99,970
-25% -$3.78M
GM icon
61
CALL
General Motors
GM
$81.8B
$12.7M 0.35%
+500,000
New +$12.2M
SWTX
62
DELISTED
SpringWorks Therapeutics
SWTX
$12.6M 0.35%
300,000
-50,000
-14% -$1.78M
PRNB
63
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$12M 0.33%
200,000
-50,000
-20% -$3.09M
STNE icon
64
StoneCo
STNE
$2.67B
$11.2M 0.31%
290,000
-110,000
-28% -$3.21M
AGEN
65
Agenus
AGEN
$274M
$11.2M 0.31%
145,208
+17,833
+14% +$1.07M
CYCN icon
66
Cyclerion Therapeutics
CYCN
$14.9M
$10.9M 0.3%
92,079
-1,000
-1% -$83.6K
DNLI icon
67
Denali Therapeutics
DNLI
$3.79B
$10.9M 0.3%
450,000
-50,000
-10% -$1.18M
SYRE icon
68
Spyre Therapeutics
SYRE
$8.35B
$10.2M 0.28%
44,000
+28,000
+175% +$5.33M
BNTX icon
69
CALL
BioNTech
BNTX
$23.4B
$10M 0.28%
+150,000
New +$7.49M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$9.73M 0.27%
234,000
-116,000
-33% -$4.21M
NBP
71
NovaBridge Biosciences American Depositary Shares
NBP
$193M
$9.7M 0.27%
324,000
-26,000
-7% -$538K
ASND icon
72
Ascendis Pharma A/S
ASND
$16.8B
$9.61M 0.27%
65,000
-35,000
-35% -$4.81M
KURA icon
73
Kura Oncology
KURA
$793M
$9.42M 0.26%
578,000
+178,000
+45% +$2.57M
ADPT icon
74
Adaptive Biotechnologies
ADPT
$3.53B
$9.1M 0.25%
188,000
-12,000
-6% -$438K
AXDX
75
DELISTED
Accelerate Diagnostics
AXDX
$8.89M 0.25%
58,650
-1,350
-2% -$133K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group deployed $318M of net new capital in Q2 2020, opening 39 new positions and adding to 22 existing holdings. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $137M trimmed.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.